Gamida Cell News Today

CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ:XRTX, TSXV:XRTX, Frankfurt: ANUA WKN: A3UNZ)), a late-stage clinical pharmaceutical company

U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow traded down 0.02% to 39,753.17 while the NASDAQ fell 0.08% to 16,385.80. The S&P 500 also rose, gaining, 0.04% to 5,250.38.

U.S. stocks traded mixed this morning, with the Dow Jones index trading almost flat on Thursday. Following the market opening Thursday, the Dow t...

Gamida Cell Stock (NASDAQ: GMDA) stock price, news, charts, stock research, profile.

Companies Reporting Before The Bell • Local Bounti (NYSE:LOCL) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.

Gamida Cell (NASDAQ: ) just reported results for the fourth quarter of 2023. InvestorPlace Earnings is a project that leverages data from TradeSmith to…

Gamida Cell Ltd. (GMDA), a company focused on cell therapy, on Wednesday reported a narrower loss for the full year, supported by an increase in financial income of $14.

Gamida Cell Ltd. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 1.78 million. Net loss was USD 63 million compared to USD...

The Israeli stem cell company will lay off 25% of its workforce and close its Jerusalem development center.

Gamida Cell shares plummet as the company enters a restructuring agreement with Highbridge Capital Management, aiming to secure long-term financial stability.